Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
,
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
1 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
2 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
3 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
4 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
5 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
6 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
7 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
8 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
9 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Several recent studies in mCRPC have identified the mechanisms of tumoral growth after the disease becomes unresponsive to standard hormonal therapy. These studies have highlighted the importance of residual intratumoral androgens in maintaining androgen receptor (AR) transcriptional activity in mCRPC [1] . Based on this findings , it has been possible to develop drugs, blocking the key enzyme in the biosynthesis of androgens through the inhibition of cytochrome p450 17 (CYP17) such as Abiraterone Acetate (AA) and drugs which directly target the AR including Enzalutamide (E) and Orteronel. Before this new knowledge, mCRPC treatment benefited from chemotherapy with taxanes. Recently a new taxane, Cabazitaxel (C), was approved in second line setting in association with prednisone. Retrospective analyses have tried to clarify the current role of chemotherapy in mCRPC patients and the right chemotherapy sequence of use of chemotherapy compared to new hormonal agents . Moreover, it would be important to address changes in the endpoints used in clinical trials, based on the stage of disease including the presence tumor-related symptoms, in order to identify the right therapeutic strategy.
D. J. Bedoya and N. Mitsiades, “Clinical Appraisal of Abiraterone in the Treatment of Metastatic Prostatic Cancer: Patient Considerations, Novel Opportunities, and Future Directions,” OncoTargets and Therapy, Vol. 2013, No. 6, 2013, pp. 9-18. doi:10.2147/OTT.S24941
Office for National Statistics, “Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England,” MB1: No. 39 Edition, Office for National Statistics, London, 2010.
Office for National Statistics, “Statistical Bulletin: Death Registrations by Cause in England and Wales, 2009,” Office for National Statistics, London, 2010.
B. J. Feldman and D. Feldman, “The Development of Androgen-Independent Prostate Cancer,” Nature Reviews: Cancer, Vol. 1, No. 1, 2001, pp. 34-45. doi:10.1038/35094009
R. B. Montgomery and E. A. Mostaghel, “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth,” Cancer Research, Vol. 68, No. 11, 2008, pp. 4447-4454. doi:10.1158/0008-5472.CAN-08-0249
A. J. Armstrong and I. F. Tannock, “The Development of Risk Groups in Men with Metastatic Castration-Resistant Prostate Cancer Based on Risk Factors for PSA Decline and Survival,” European Journal of Cancer, Vol. 46, No. 3, 2010, pp. 517-525. doi:10.1016/j.ejca.2009.11.007
C. J. Ryan, M. R. Smith, et al., “Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy,” The New England Journal of Medicine, Vol. 368, No. 2, 2013, pp. 138-148. doi:10.1056/NEJMoa1209096
I. F. Tannock, R. De Wit, et al., “Docetaxel plus Prednisone or Mitoxantrone plus Prednisone,” The New England Journal of Medicine, Vol. 351, 2004, pp. 1502-1512. doi:10.1056/NEJMoa040720
I. F. Tannock, I. Osoba, et al., “Chemotherapy with Mitoxantrone plus Prednisone or Prednisone Alone for Symptomatic Hormone-Resistant Prostate Cancer: A Canadian Randomized Trial with Palliative End Points,” Journal of Clinical Oncology, Vol. 14, No. 6, 1996, pp. 1756-1764.
J. C. Eymard, S. Oudard, et al., “Docetaxel Reintroduction in Patients with Metastatic Castration-Resistant Docetaxel-Sensitive Prostate Cancer: A Retrospective Multicentre Study,” BJU International, Vol. 106, No. 7, 2010, pp. 974-978. doi:10.1111/j.1464-410X.2010.09296.x
Y. Loriot, C. Massard, et al., “The Interval from the Last Cycle of Docetaxel-Based Chemotherapy to Progression Is Associated with the Efficacy of Subsequent Docetaxel in Patients with Prostate Cancer,” European Journal of Cancer, Vol. 46, No. 10, 2010, pp. 1770-1772. doi:10.1016/j.ej ca.2010.04.010
G. Di Lorenzo, C. Buonerba, et al., “Phase II Study of Docetaxel Re-Treatment in Docetaxel-Pretreated Castration-Resistant Prostate Cancer,” BJU International, Vol. 107, No. 2, 2011, pp. 234-239. doi:10.1111/j.1464-410X.2010.09498.x
G. Attard, A. H. Reid, et al., “Selective Inhibition of CYP17 with Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer,” Journal of Clinical Oncology, Vol. 27, No. 23, 2009, pp. 3742-3748. doi:10.1200/JCO.2008.20.0642
C. J. Ryan, M. R. Smith, et al., “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients with Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy,” Journal of Clinical Oncology, Vol. 28, No. 9, 2010, pp. 1481-1488.
D. C. Danila, M. J. Morris, et al., “Phase II Multicenter Study of Abiraterone Acetate plus Prednisone Therapy in Patients with Docetaxel-Treated Castration-Resistant Prostate Cancer,” Journal of Clinical Oncology, Vol. 28, No. 9, 2010, pp. 1496-1501.
C. J. Logothetis, E. Basch, et al., “Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial,” The Lancet Oncology, Vol. 13, No. 12, 2012, pp. 1210-1217. doi:10.1016/S1470-2045(12)70473-4
C. N. Sternberg, A. Molina, et al., “Effect of Abiraterone Acetate on Fatigue in Patients with Metastatic CastrationResistant Prostate Cancer after Docetaxel Chemotherapy,” Annals of Oncology, Vol. 24, No. 4, 2012, pp. 1017-1025.
F. Calcagno, T. Nguyen, et al., “Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer,” Clinical Medicine Insights: Oncology, Vol. 7, 2013, pp. 1-12.
A. C. Mita, L. J. Denis, et al., “Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors,” Clinical Cancer Research, Vol. 15, No. 2, 2009, pp. 723-730. doi:10.1158/1078-0432.CCR-08-0596
J. S. De Bono, S. Oudard, et al., “Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomized Open-Label Trial,” The Lancet, Vol. 376, No. 9747, 2010, pp. 1147-1154. doi:10.1016/S0140-6736(10)61389-X
Y. S. Ha, S. Goodin, et al., “Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer,” Drugs Today, Vol. 49, No. 1, 2013, pp. 7-13.
H. I. Scher, K. Fizazi, et al., “Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy,” The New England Journal of Medicine, Vol. 367, No. 13, 2012, pp. 1187-1197. doi:10.1056/NEJMoa1207506
A. Berruti, D. Generali, et al., “Enzalutamide in Prostate Cancer after Chemotherapy,” The New England Journal of Medicine, Vol. 367, No. 25, 2012, pp. 2448-2449. doi:10.1056/NEJMc1212940
J. Mezynski, C. Pezaro, et al., “Antitumor Activity of Docetaxel Following Treatment with CYP17A1 Inhibitor Abiraterone: Clinical Evidence for Cross-Resistance?” Annals of Oncology, Vol. 23, No. 11, 2012, pp. 2943-2947. doi:10.1093/annonc/mds119
L. Albiges and S. Le Moulec, “Response to Cabazitaxel in the Postchemotherapy Setting in CRPC Patients Previously Treated with Docetaxel and Abiraterone Acetate,” European Society for Medical Oncology (ESMO), Vienna, 2012.
D. Bianchini, Y. Loriot, et al., “Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study,” European Society for Medical Oncology (ESMO), Vienna, 2012.
K. Noonan and S. Ellard, “Clinical Activity of Abiraterone Acetate (AA) after Progression on mdv3100 in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) Abstract,” European Society for Medical Oncology (ESMO), Vienna, 2012.
D. Rathkopf, “COU-AA-302, a Randomized Phase 3 Study of Abiraterone Acetate in Metastatic CastrationResistant Prostate Cancer Patients without Prior Chemotherapy,” American Society of Clinical Oncology (ASCO), Alexandria, 2013.